Integra Lifesciences Hldgs Cp Stock Price, News & Analysis

Integra LifeSciences (Nasdaq: IART) has announced the enrollment of its first patient in the Acclarent AERA Pediatric Registry, a significant milestone in pediatric Eustachian tube dysfunction (ETD) treatment research. The registry will evaluate the real-world use of the AERA Eustachian Tube Balloon Dilation System in children.

The multi-center observational study aims to enroll up to 300 pediatric patients across 20 U.S. sites. Dr. Prasad Thottam at Michigan Pediatric ENT Associates enrolled the first patient. The registry will track safety and efficacy outcomes, with the primary endpoint focusing on failure-free status following the procedure. Secondary endpoints include various clinical measurements and patient-reported outcomes.

Integra LifeSciences (NASDAQ: IART) reported Q1 2025 financial results with revenues of $382.7M, showing a 3.7% reported increase but a 3.5% organic decline year-over-year. The company posted a GAAP net loss of $(0.33) per share, compared to $(0.04) in the prior year, and adjusted EPS of $0.41, down from $0.55. The Codman Specialty Surgical segment (~70% of revenues) reached $280.7M with 9.4% reported growth, while Tissue Technologies (~30%) declined 9.3% to $102.0M. The company maintained its full-year 2025 revenue guidance of $1.650B-$1.715B but reduced adjusted EPS guidance to $2.19-$2.29 due to new tariff impacts. For Q2 2025, Integra expects revenues between $390M-$400M and adjusted EPS of $0.40-$0.45.

Integra LifeSciences (NASDAQ: IART), a global medical technology company, has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET the same day to discuss the results.

Investors can access a live webcast through the company's investor relations website at investor.integralife.com. Those wishing to participate in the call must register to receive dial-in details and an individual pin. Participants are advised to join 10 minutes before the event starts. A replay of the webcast will be available on the company's investor section after the call.

Integra LifeSciences (NASDAQ: IART) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. CEO Mojdeh Poul and CFO Lea Knight will deliver a presentation on March 17, 2025, at 10:00am ET.

The global medical technology company will provide a live webcast of the presentation, which will be accessible through their investor relations website at investor.integralife.com/events-and-presentations.

Integra LifeSciences (NASDAQ: IART) reported Q4 2024 revenues of $442.6 million, an 11.5% increase (3.5% organic growth) compared to Q4 2023. Q4 adjusted EPS was $0.97, up from $0.89 in the prior year period.

For full-year 2024, revenues reached $1,610.5 million, representing a 4.5% increase on a reported basis but a 1.3% decrease organically compared to 2023. Full-year adjusted EPS was $2.56, down from $3.10 in 2023.

The company's Codman Specialty Surgical segment (71% of revenues) grew 15.8% on a reported basis and 4.1% organically in Q4, while Tissue Technologies (29% of revenues) increased 2.1% both on a reported and organic basis.

For 2025, Integra expects revenues between $1,650-$1,715 million (2.4-6.5% reported growth) and adjusted EPS of $2.41-$2.51. Q1 2025 revenue is projected at $375-$385 million with adjusted EPS of $0.40-$0.45.

Integra LifeSciences (NASDAQ: IART) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results.

Investors can access a live webcast through the company's investor relations website. Those wishing to participate in the call need to register to receive dial-in details and an individual pin. The company recommends joining 10 minutes before the start time. A replay of the webcast will be available on the company's investor website after the call.

Integra LifeSciences (Nasdaq: IART) has launched the Integra Institute, a new global medical education platform designed for healthcare professionals (HCPs). The digital platform offers on-demand learning resources focusing on surgical, neurologic, ENT, and regenerative care across the United States and EMEA regions.

The platform features curated content including on-demand webinars covering complex medical scenarios, surgical videos demonstrating latest techniques, and an events calendar for continuous learning and networking opportunities. The initiative aims to provide a comprehensive professional development resource for healthcare providers at various experience levels.

Dr. Said Azoury, plastic and reconstructive surgeon at the Hospital of the University of Pennsylvania, endorsed the platform's potential for facilitating convenient learning and collaboration. Healthcare professionals can access the platform by registering at institute.integralife.com.

A new economic study published in the Journal of Comparative Effectiveness Research demonstrates significant cost savings when using Integra's DuraSeal Polyethylene Glycol (PEG) hydrogel instead of fibrin glue in posterior cranial fossa surgeries. The analysis, conducted across five European countries (Belgium, France, Germany, Italy, and UK), shows cost savings ranging from €419 to €1,279 per patient, representing an average 22% cost reduction per procedure (15% in Italy).

The study is based on a prospective observational study of 200 patients and reveals that DuraSeal's effectiveness at preventing cerebrospinal fluid (CSF) leaks leads to reduced hospital stays and fewer post-surgical interventions. Despite higher upfront costs, DuraSeal proves to be a cost-effective alternative to fibrin glue in PCF surgery across European healthcare systems.

Integra LifeSciences (NASDAQ: IART) reported Q3 2024 financial results with revenues of $380.8 million, showing a 0.4% decrease on a reported basis and 8.6% decline organically compared to last year. The company posted a GAAP loss of $(0.14) per share, down from $0.24 in the prior year, while adjusted EPS fell to $0.41 from $0.76.

The Codman Specialty Surgical segment (~70% of revenues) reached $270.8 million with 1.0% reported growth, while Tissue Technologies (~30%) declined 3.6% to $110.1 million. The company updated its full-year 2024 guidance to $1.609-1.619 billion in revenue and adjusted EPS of $2.41-2.49.